Actinogen Medical Company Profile, Contacts & Intelligence

BiotechnologyAu16 employeesFounded 2014
3 contacts with email or phone data3 with email data1 with phone data
Employees
16
Company source estimate
Reachable Contacts
3
Visible contacts with email or phone data
Contacts With Email
3
3 of 4 visible contacts
Departments
4
Mapped contact coverage

Actinogen Medical Overview

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms. Actinogen’s lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimer’s Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment. Actinogen has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. The Company is rapidly moving forward into its upcoming double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential. The XanaMIA Phase 2b AD trial comprises 330 patients with mild Alzheimer’s Disease and the XanaCIDD Phase 2a trial will total 160 patients with depression.

Headquarters
Au
Industry
Biotechnology
Founded
2014
Phone Number
Available in AeroLeads
Company Email
Available in AeroLeads

Actinogen Medical Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

3 contacts with contact data
3 with email data and 1 with phone data in the visible sample.
4 departments represented
Visible contacts with email or phone data are mapped to these departments.
3 company-domain emails
Visible contacts using Actinogen Medical's company email domain.
Executive
2
Healthcare
1
Marketing
1
General
1

Actinogen Medical People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Actinogen Medical Workforce Composition

Seniority breakdown across 11 visible profiles.

Executive
3
Senior / Lead
3
Individual contributor
3
Director
1
Manager
1

Actinogen Medical Technology & Talent

Technology-related job titles represented in the visible people data.

Data / AI
2

Compare Similar Companies to Actinogen Medical

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
uniQure Biotechnology Research 311 View company
AC Immune Biotechnology Research 178 View company
Alpha Cognition, Inc. Pharmaceutical Manufacturing 52 View company
Neuphoria Therapeutics Inc Biotechnology Research 36 View company
Noema Pharma Biotechnology 33 View company
Relmada Therapeutics, Inc Pharmaceutical Manufacturing 32 View company
Eikonizo Therapeutics Biotechnology 14 View company
NeuClone Pharmaceutical Manufacturing 9 View company
Anthrocell Pty Ltd Biotechnology 4 View company
Kariya Pharmaceuticals Biotechnology Research 4 View company